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ORIGINAL ARTICLE: Clinical Endoscopy
Outcomes of screening gastroscopy in ﬁrst-degree relatives of
patients fulﬁlling hereditary diffuse gastric cancer criteria
Rachel S. van der Post, MD,1 Jolanda van Dieren, MD, PhD,2 Anna Grelack, MD,3
Nicoline Hoogerbrugge, MD, PhD,4 Lizet E. van der Kolk, MD, PhD,5 Petur Snaebjornsson, MD, PhD,6
Iris Lansdorp-Vogelaar, PhD,7 J. Han van Krieken, MD, PhD,1 Tanya M. Bisseling, MD, PhD,3
Annemieke Cats, MD, PhD2
Nijmegen, Amsterdam, Rotterdam, the Netherlands
Background and Aims: The aim of this study was to determine the yield of endoscopic screening in ﬁrst-degree
relatives (FDRs) of CDH1-negative hereditary diffuse-type gastric cancer (HDGC) patients.
Methods: In this retrospective observational cohort study, in 2 expert centers in the Netherlands data were
collected on FDRs from families fulﬁlling the international HDGC criteria that underwent endoscopic screening.
Extensive inspection of the stomach was performed by gastroscopy, taking random and/or targeted stomach
biopsy specimens to identify diffuse-type gastric cancer.
Results: Between 2004 and 2016, 90 persons (40% men; mean age, 48 years) from 40 families were offered endo-
scopic screening. The mean number of endoscopies per person was 3. The mean follow-up time was 46 months
and mean endoscopic interval 20 months. Signet ring cell carcinoma foci restricted to the mucosa (pT1a) were
identiﬁed in 4 persons (4%) from 1 family, which afterward was diagnosed with a germline CTNNA1 mutation.
Advanced poorly cohesive gastric carcinoma was diagnosed in 1 person from another family. Intestinal metaplasia
was diagnosed in 38 persons (42%) and low-grade dysplasia in 4 persons (4%). Additionally, in 40 persons (44%)
scar tissue was observed in the gastric mucosa, which can hinder the endoscopic detection of small white lesions
typical for HDGC.
Conclusions: Endoscopic screening in HDGC families without a pathogenic CDH1 mutation may be reasonable,
as we detected signet ring cell carcinomas in 6% of persons screened. However, the criteria and frequency of
screening may have to be reconsidered. (Gastrointest Endosc 2018;87:397-404.)
Comparable with other Western countries, the inci-
dence of noncardia gastric cancer has markedly declined
in the Netherlands during the last decades.1,2 In particular,
the incidence of intestinal-type gastric cancer has
decreased, but the incidence of diffuse-type gastric cancer
(DGC) seems to be increasing.3-6 Younger gastric cancer
patients especially are more often diagnosed with DGC.7-9
Intestinal-type gastric cancer can largely be attributed to
Helicobacter pylori infections in a genetically susceptible
host according to the Correa sequence,10 but the
pathogenesis of DGC is less well understood. It has been
suggested that H pylori plays a role in the development
of DGC as well.11,12 In DGC genetic variations may play
an important role. However, recent exome sequencing
Abbreviations: DGC, diffuse-type gastric cancer; FDR, first-degree rela-
tive; HDGC, hereditary diffuse-type gastric cancer; SRCC, signet ring
cell carcinoma.
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studies in families that fulﬁll criteria of hereditary DGC
(HDGC) failed to identify monogenic causes in most
families.13,14 Mainly pathogenic CDH1 mutations, causing
a dysfunction in the adhesion molecule E-cadherin, are
found in a select group of HDGC families.14,15
Individuals with heterozygous CDH1 mutations have a
high cumulative risk of up to 70% to develop DGC.14
Because DGC develops from small mucosal foci of signet
ring cells with a diffuse scattered growth pattern, it can
be difﬁcult to detect DGC by endoscopy, even in
advanced stages. Therefore, prophylactic gastrectomy is
offered to individuals with conﬁrmed pathogenic CDH1
mutations. Depending on personal circumstances and
preferences, some patients opt for annual endoscopic
surveillance according to the Cambridge protocol.16
Surveillance studies have shown that small, pale,
nonelevated lesions can represent early-stage DGC, histo-
logically showing signet ring cells within the lamina
propria.16,17 However, these lesions can be difﬁcult to
detect as becomes apparent from the observation that
even in experienced hands, endoscopy often reveals no
abnormalities or only a few pale lesions, whereas resection
specimens show tens to hundreds of small signet ring cell
carcinomas (SRCCs).18-21
More than 70% of HDGC probably cannot be attributed
to a germline CDH1 mutation.14,22,23 The risk of devel-
oping DGC for these families is unknown but is presum-
ably lower than reported in CDH1 families. Little is
known about the outcomes of screening in ﬁrst-degree
relatives (FDRs) of patients who fulﬁll HDGC criteria but
tested negative for pathogenic CDH1 gene mutations.
Although evidence is lacking, the HDGC consensus guide-
line suggests annual endoscopic screening for FDRs of
patients fulﬁlling HDGC criteria but without a detectable
genetic defect.16 In the current study we describe
the outcomes of endoscopies in FDRs from HDGC
families without a pathogenic germline CDH1 mutation.




This study, conducted by the Netherlands Cancer Insti-
tute/Antoni van Leeuwenhoek (NKI/AVL) and Radboud
University Medical Center, is a retrospective observational
cohort study. All clinicopathologic data were collected
from medical records and anonymously stored in a com-
bined database from persons who underwent endoscopic
gastric screening between March 2004 and September
2016. Persons older than age 18 years who were FDRs of
an affected person in a family fulﬁlling the updated
HDGC criteria of 2015 were included (Table 1).16
Families were only included if genetic counseling had
been performed. Family pedigrees of at least 3 generations
were analyzed for the number of affected family members
with gastric cancer and other malignancies. Germline
CDH1 mutation analysis was performed in the affected
patient with gastric cancer (index patient). When the
DNA of an affected patient was not available, 1 or more
relatives were tested to exclude a pathogenic germline
CDH1 mutation. Testing for other gene mutations,
including TP53, mismatch repair genes, PTEN, BRCA1/2,
STK11, SMAD4, and BMPR1a, was performed when the
family met the criteria for testing of that speciﬁc cancer
syndrome according to the national and international
guidelines.16,24,25 The original histopathologic reports
from patients with gastric cancer were reviewed to conﬁrm
the diagnosis of DGC.
Information of persons was collected on age at endos-
copy, number of endoscopies, prior malignancies, prior
infection with H pylori, endoscopic abnormalities, endo-
scopic signs of scar formation, histopathologic ﬁndings of
gastritis, H pylori infection, atrophy, intestinal metaplasia,
dysplasia, and carcinoma. All persons from both centers
were informed about the current screening guideline, the
lack of evidence for endoscopic screening, and its proce-
dural related risk. All persons gave their informed consent.
Endoscopic screening protocol
At NKI/AVL an endoscopic screening program for persons
at risk for the development of DGC started in 2004. At the
Radboud University Medical Center the endoscopic
screening protocol started from 2010 onward. Endoscopy
was performed with the patient under conscious sedation
with midazolam or propofol. From November 2008 onward,
after the International Gastric Cancer Linkage Consortium
consensus meeting, gastroscopies were performed in line
with the consensus protocol.26 During at least 30 minutes
the gastric mucosa was thoroughly inspected, searching
for lesions that might be typical for early DGC. A biopsy
specimen was taken from each aberrant mucosal lesion.
Additionally, multiple random specimens were taken from
each of the following anatomic regions of the stomach:
antrum, transitional zone, body, fundus, and cardia.
Although there was no strict screening protocol before
2008, all gastroscopies were performed with thorough
inspection, often with both targeted and random biopsy
specimens from the gastric mucosa.
The endoscopic screening at NKI/AVL and Radboud
University Medical Center was performed or supervised
by 1 of 3 gastroenterologists (A.C., J.v.D., T.M.B.) with
experience in HDGC. At NKI/AVL a white-light high-deﬁni-
tion endoscope with narrow-band imaging (GIF-H180/GIF-
H190; Olympus, Tokyo, Japan) was used from 2008. At the
Radboud University Medical Center the Pentax 3.2 EG29-
i10 with iscan modality (Pentax, Tokyo, Japan) was used
from 2014. Before that period Olympus 160-series endo-
scopes (Olympus, Tokyo, Japan) were used at both cen-
ters. Although the protocol does not describe screening
with narrow-band imaging, it was used extensively at our
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centers because it facilitates visualization of the gastric pit
structure and the typical white lesions that may represent
signet ring cell foci.
Persons were included if they underwent at least 1
screening gastroscopy with more than 10 random biopsy
samples from at least 4 anatomic regions. Endoscopies
were included if the goal of the gastroscopy was screening.
Endoscopies for evaluation of complaints or interval endos-
copies for follow-up of dysplasia or cancer were noted but
excluded from the analysis.
Histologic sampling and examination of biopsy
specimens from the gastric mucosa
The primary outcome measure was the endoscopic
yield of microscopic early-stage DGC (including mucosal
signet ring cell foci). Other lesions associated with (espe-
cially intestinal-type) gastric cancer, such as atrophic
gastritis, intestinal metaplasia, and dysplasia, are consid-
ered secondary ﬁndings because the relationship of these
lesions and DGC is not clear. Experienced pathologists
analyzed all gastric biopsy specimens. Biopsy specimens
were examined using standard stains: hematoxylin and
eosin and periodic acid Schiff-diastase (mucin-stain).
Additional (immuno-)histochemical stains were used in
case of gastritis for the detection of H pylori or to detect
or conﬁrm another speciﬁc diagnosis.
RESULTS
Baseline characteristics
Between March 2004 and September 2016, 90 persons
from 40 families fulﬁlling the 2015 HDGC criteria
underwent endoscopic screening of the stomach. The
baseline characteristics, including number of persons
and family per HDGC criterion, are shown in Table 1
and Supplementary Table 1 (available online at www.
giejournal.org). In total, 285 endoscopies were
performed during the 12.5 years of the study, 52 before
November 2008. Forty percent of the persons were men.
The mean age (during the ﬁrst endoscopy of each
person) was 48 years (standard deviation, 12.9; range,
22-72). One to 18 family members were screened per
family. In 75 persons (83%) at least 25 random biopsy
samples of 5 gastric regions were taken during at least
1 endoscopy; in the other 15 persons more than 10




Total number of endoscopies 285
Mean interval between endoscopies, mo (SD; range)* 20 (17; 7-129)
Mean follow-up time, mo (SD; range)* 46 (40; 9-146)
Mean number of endoscopies per person (SD; range) 3 (3; 1-12)
Mean number of biopsy samples (range)y 27 (0-52)
Mean number of random biopsy samples (range)z 25 (3-46)
Mean number of targeted biopsy samples (range)x 5 (1-24)
Endoscopies with 25 biopsy samples of 5 anatomic areas 157 (55)
Mean age during the first endoscopy, y (SD; range) 48 (13; 22-72)
HDGC criteria 2010,26 no. of persons (no. of families) 59 (30)
3 first- or second-degree family members with a diagnosis of DGC independent of age 7 (4)
2 cases of gastric cancer in first- or second-degree relatives, 1 confirmed DGC before age 50 y 26 (13)
Individual with DGC diagnosed before age 40 y 25 (12)
Combination of DGC and LBC in first- or second-degree relatives, 1 diagnosed before age 50 y 1 (1)
Not fulfilling HDGC criteria 2010 31 (10)
HDGC criteria 2015,16 no. of persons (no. of families) 90 (40)
2 cases of gastric cancer in first- or second-degree relatives, 1 confirmed DGC independent of age 64 (27)
Individual with DGC diagnosed before age 40 y 25 (12)
Combination of DGC and LBC in first- or second-degree relatives, 1 diagnosed before age 50 y 1 (1)
Values are number of cases with percents in parentheses unless otherwise indicated.
SD, Standard deviation; HDGC, hereditary diffuse gastric cancer; DGC, diffuse gastric cancer; LBC, lobular breast cancer.
*Included are 69 persons (21 persons had only 1 endoscopy and no follow-up).
yIncluded are all endoscopies (in 2 no biopsy specimens were taken).
zIncluded are 270 endoscopies (in 15 no random biopsy specimens were taken).
xIncluded are 188 endoscopies (in 97 no targeted biopsy specimens were taken).
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random biopsy samples were taken of at least 4 anatomic
regions. Twenty-one persons underwent only 1 endoscopy,
30 underwent 2 endoscopies, and 39 persons had 3 or
more endoscopies. The mean endoscopic interval for per-
sons receiving more than 1 endoscopy was 20 months, and
mean follow-up time was 46 months. None of the persons
had a known medical history of gastric dysplasia or malig-
nancy. Germline pathogenic CDH1 mutation was excluded
in all families, in 32 families by testing the DGC (index)
patient and in 8 families by testing 1 or more family mem-
bers of the index patient because no genetic material was
available from the index patient.
Yield of the screening program
DGC was detected in 5 persons, and all cases were
stage I (Table 2). In 1 person a highly suspicious tumor
in the gastric body was detected during endoscopy
(Table 3), whereas in the other persons the ﬁnding of
DGC was found in random biopsy specimens. Well-
deﬁned small pale lesions that can represent small signet
ring cell foci, as described in CDH1 mutation carriers,
were not found. The most advanced tumor was detected
in a woman of 51 years (H190 endoscope, Olympus, To-
kyo, Japan). She was ﬁrst screened at age 44, and Barrett’s
mucosa with high-grade dysplasia was detected in the
distal esophagus. After ablative treatment of the Barrett’s
esophagus, followed by 7 years without endoscopic
screening, a nonsymptomatic tumor of 2 cm was found
in the greater curvature of the body of the stomach, which
was conﬁrmed DGC histologically (Fig. 1A and B). After
treatment with neoadjuvant chemotherapy, the resection
specimen showed a diffuse carcinoma in the body of the
stomach of 7 cm, growing into the peritoneal surface
with omental metastases (ypT4aN0M1 DGC). Four
siblings were previously diagnosed with advanced DGC
(diffuse-type histology was reviewed and conﬁrmed).
Germline CTNNA1 mutation was excluded in 2 siblings
with DGC using Sanger sequencing.
In 4 other persons mucosal foci (pT1a) of SRCC were
diagnosed (Fig. 1C and D). The ﬁrst case was a 75-year-
old man. SRCC was found in the fundus with random bi-
opsy sampling without visible lesions (H180 endoscope)
in 2010. Three earlier (2004-2008) and 5 later (2011-
2015) gastroscopies with H180 and H190 endoscopes
with biopsy sampling did not reveal abnormalities in this
patient. In the second case, a 42-year-old man, random
biopsy specimens from the cardia showed SRCC foci in
2005 and 2006 (a second and third screening). No visible
lesions were seen (GIF Q160 scope, Olympus, Tokyo,
Japan). No endoscopic or histologic abnormalities were
found in 2 following gastroscopies. In 2010, again SRCC
was found in the cardia without endoscopic visible lesions
(H180 endoscope). Gastrectomy was performed afterward.
Multiple T1a SRCC foci were found in the resection spec-
imen. Two other men aged 40 and 41 years, respectively,
underwent their ﬁrst gastroscopy in 2010 (H180 endo-
scope). No endoscopic lesions were found, but random bi-
opsy specimens revealed SRCC foci, in the fundus in 1 and
in fundus and cardia in the second. In both men gastrec-
tomy was performed, and multiple T1a SRCC foci were
found in both gastrectomy specimens.
These 4 people with SRCC foci belonged to 1 family (in
which a total of 18 members were screened). The people
in this family were included because of the ﬁrst HDGC
criterion (families with 2 ormore patients with gastric cancer
at any age, 1 conﬁrmed DGC). In an additional family mem-
ber of this speciﬁc family there was, next to intestinal meta-
plasia, a single atypical gland suspicious for in situ SRCC.
However, more extensive abnormalities could not be
conﬁrmed in 6 follow-up endoscopies during the next 5
years. The ﬁndings in this family led to exome sequencing,
which revealed a mutation in the CTNNA1 gene, encoding
the alpha-E-catenin molecule.27 In the other 38 families no
other gastric malignancies were detected.
Low-grade dysplasia was diagnosed in 4 persons (4%)
(Fig. 1E and F), of whom 2 belonged to the same family
in which a pathogenic CTNNA1 mutation was detected.
In the ﬁrst person (man, 63 years) low-grade dysplasia
was found in a random biopsy specimen in the antrum
(2005, GIF Q160 scope). In the second person (woman,
64 years) there was a small elevation in the fundus, which
was diagnosed histologically as a tubulovillous adenoma
with low-grade dysplasia (2014, H180 endoscope). Later
analysis showed the man was a carrier of the CTNNA1
mutation, whereas the woman was not. In a third person
(man, 47 years) the transitional zone showed a patchy
aspect endoscopically, which histologically was diagnosed
as extensive intestinal metaplasia and low-grade dysplasia
within a background of chronic inﬂammation (2014,
EG29-i10 endoscope, Pentax, Tokyo, Japan). In the fourth
person (man, 62 years) erosive lesions were found in the
antrum, which was microscopically diagnosed as extensive
TABLE 2. Biopsy samples with diffuse gastric cancer, dysplasia, and intestinal metaplasia
Families Persons Endoscopies Biopsy samples Random biopsy samples Targeted biopsy samples
Total 40 (100) 90 (100) 285 (100) 7751 (100) 6825 (100) 926 (100)
Diffuse gastric cancer 2 (5) 5 (6) 7 (2) 27 (.3) 7 (.1) 20 (2)
Dysplasia 3 (8) 4 (4) 4 (1) 5 (.06) 2 (.03) 3 (.3)
Intestinal metaplasia 21 (53) 38 (42) 84 (29) 302 (4) 212 (3) 90 (10)
Values in parentheses are percents.
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intestinal metaplasia with low-grade dysplasia (2013, EG29-
i10 endoscope). In the last person low-grade dysplasia was
diagnosed again in biopsy samples taken in a second
endoscopy after 3 months. Follow-up endoscopies in the
following 3 years did not show dysplasia. In the other 3
persons, low-grade dysplasia was detected only once and
was not diagnosed during follow-up endoscopies and
biopsy sampling (follow-up 1.5, 3, and 10 years).
Intestinal metaplasia was diagnosed in 84 of 285 endos-
copies performed (29%) (Fig. 1G and H). The biopsy
specimens with intestinal metaplasia belonged to 38
persons (42%) with a mean age at diagnosis of 52 years
(standard deviation, 12.5; range, 30-76). Intestinal
metaplasia was isolated to the distal region (antrum,
pylorus, and transitional zone) of the stomach in 63%.
Intestinal metaplasia was found in 29% multifocal, in 3%
proximal (cardia), and in 5% in the gastric fundus and/or
body. Nonspeciﬁc chronic inﬂammation was the most
common abnormality of the gastric mucosa in all persons
(60 persons, 67%). Twenty-two persons had signs of active
gastritis (24%) with histologically H pylori inﬂammation in
7 cases. An additional 10 persons had H pylori inﬂamma-
tion before screening started, and 9 of these patients also
developed intestinal metaplasia. Furthermore, subtle endo-
scopic scar formation of the gastric mucosa (Fig. 1I and J),
identiﬁed during follow-up after the ﬁrst endoscopy, was
observed in 39 persons (43%) and in 1 person during the
ﬁrst endoscopy. Biopsy samples from 82 endoscopies
(29%) did not show any abnormality (no inﬂammation, at-
rophy, intestinal metaplasia, scar formation, polyps,
dysplasia or carcinoma). No serious adverse events were
reported in medical charts after endoscopy.
DISCUSSION
During a period of 12.5 years, 90 persons from 40
HDGC families without germline CDH1 mutations were
endoscopically screened. In this endoscopic screening pro-
gram attention is paid to early-stage DGC, namely mucosal
SRCC in biopsy samples, which may be seen as small pale
lesions during endoscopy as was learned from surveillance
in CDH1mutation carriers. SRCC foci (pT1a) were found in
random biopsy samples of 4 persons from 1 family in
which additional genetic analysis revealed a germline
CTNNA1 mutation in all 4.27 In a patient from another
family, advanced DGC was found during the screening
program. In none of the other 38 families gastric cancer
was detected.
Because of the very focal nature of small mucosal
SRCCs, endoscopic detection is extremely difﬁcult, as was
demonstrated previously even in patients with a very
high chance of having SRCC foci.28,29 Therefore, endo-
scopic surveillance is not accepted as a safe alternative
for prophylactic gastrectomy in individuals with a proven
pathogenic CDH1 mutation. Our study highlights the diag-
nostic difﬁculties in individuals without a known germline
mutation, and therefore unknown risk, when advice on
prophylactic gastrectomy cannot be given. In some pa-
tients in this study after the ﬁrst positive random biopsy
sampling, follow-up biopsy samples showed negative re-
sults, to become positive again in subsequent endoscopies.
No mucosal abnormalities were visualized in these patients
during endoscopy. Possibly, the evolution of the quality of
endoscopes, the increasing resolution, and the availability
of narrow-band imaging increases the visualization of
subtle lesions, as the authors of this article experienced
in the surveillance of individuals with a germline CDH1
mutation (unpublished data). However, in the current
study we could not conﬁrm this. One could argue that a
limitation of this study is that because of the long time-
frame with long follow-up, different quality of endoscopes
have been used. However, subtle lesions could not be
visualized in screening with both older- and newer-
generation endoscopes, even in the knowledge of biopsy
specimen–proven SRCC. This ﬁnding suggests that
currently endoscopy alone without random biopsy sam-
pling is not sensitive enough as a screening modality in
our study population.
The HDGC criteria were principally set up to select fam-
ilies for genetic CDH1 testing and were recently broadened
to test more families for this devastating syndrome.16 It is
TABLE 3. Outcomes of endoscopies per anatomic location
Diagnosis Pylorus Antrum Transitional zone Body Fundus Cardia Total no.
Random Diffuse gastric cancer 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 4 (2) 7 (4)
Dysplasia 0 (0) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2)
Intestinal metaplasia 4 (4) 65 (26) 23 (10) 19 (6) 3 (3) 14 (9) 70 (29)
Total 2 (2) 265 (90) 263 (90) 267 (90) 206 (87) 256 (88) 270 (90)
Targeted Diffuse gastric cancer 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 1 (1)
Dysplasia 0 (0) 0 (0) 2 (1) 0 (0) 1 (1) 0 (0) 2 (2)
Intestinal metaplasia 10 (9) 27 (17) 14 (8) 13 (7) 3 (3) 7 (4) 38 (25)
Total 26 (19) 79 (47) 75 (48) 93 (49) 40 (29) 25 (18) 188 (82)
Values are number of endoscopies with number of persons in parentheses.
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not clear whether these CDH1 testing criteria make sense
as endoscopic screening criteria as well, when families are
proven CDH1 negative. In only .3% of the 7732 biopsy
samples in this study was invasive carcinoma found.
However, when we take into account the number of
persons and number of families enrolled, the yield of
cancer is considerable: 6% and 5%, respectively,
especially when we bear in mind that in this
Figure 1. Diffuse (poorly cohesive) gastric cancer, (A and B), endoscopy and histology of (C and D) signet ring cell carcinoma (coincidental, no speciﬁc
endoscopic ﬁndings), (E and F) low-grade dysplasia (coincidental, no speciﬁc endoscopic ﬁndings), (G and H) intestinal metaplasia, and (I and J) scar
formation.
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heterogeneous HDGC study group far less than 50% of
persons screened are at increased gastric cancer risk.
Kim et al30 developed an algorithm for gastroscopic
screening in the United States in which they proposed
screening of all individuals with an FDR with a diagnosis of
gastric cancer. They recommended screening should
begin 10 years before the age at diagnosis in the FDR or at
age 50 (whatever comes ﬁrst). It is a very topical matter of
debate when a screening program is considered useful.
Harris et al31 suggested the “balance approach” to evaluate
the usefulness of screening. Screening should only be
considered if there is evidence that the magnitude of
health beneﬁt outweighs the magnitude of harm, and this
net beneﬁt justiﬁes the required use of resources. For
well-established screening programs such as colorectal can-
cer screening, all these criteria are met. For HDGC
screening, this balance is questionable.
The current study is the largest cohort study on individ-
uals at risk for DGC described thus far. However, the
numbers presented are still too small and follow-up is
too short to calculate an accurate lifetime risk for FDRs
of CDH1-negative DGC patients fulﬁlling HDGC criteria.
Lim et al18 described screening in 7 persons fulﬁlling
HDGC criteria without CDH1 mutations and found SRCC
foci in 2 of 7 persons (28%). For a more accurate risk
calculation for the development of DGC in non-CDH1
HDGC families, larger studies with long follow-up are
needed. In addition to large cohort follow-up, our
suggestion for future research is to also use existing large
genealogy databases. Several Scandinavian countries,
Australia,32 and the state of Utah in the United States33
have genealogy databases that include large numbers of
people. These databases could be linked to cancer
registries and hospital data to identify families with
HDGC and determine risk in family members.
Interestingly, biopsy specimens in this cohort revealed a
much higher incidence of dysplasia (4%) and intestinal
metaplasia (42%) than generally reported in the
Netherlands. Both are associated with H pylori infection
and believed to be risk factors in the development of
gastric cancer, especially IGC.34-37 Den Hoed et al38
investigated the prevalence of premalignant gastric
lesions in 383 asymptomatic patients (without a family
history of gastric cancer) by taking 2 biopsy specimens
from the antrum and 2 from the body. Dysplasia was
found in 1.4% of subjects. They found intestinal
metaplasia in 7% of subjects, increasing to 13% in those
aged 60 to 70 years.38 H pylori infection was
demonstrated in 22% of persons in their study and is in
line with our results (19%). Our high frequency of
dysplasia and intestinal metaplasia may be inﬂuenced by
a more extensive inspection and biopsy sampling
protocol; a 30-biopsy sampling protocol has, to our knowl-
edge, not been described in a healthy control group of per-
sons without a family history of gastric cancer. Another
possibility is that gastric cancer in families without a
conﬁrmed monogenic cause is a pathophysiologically
different, more heterogenic, kind of cancer.
In the 285 endoscopies performed in this study, no
serious adverse events occurred, and although gastroscopy
is not without adverse event risks, it is a relatively safe
procedure. We report scar formation of gastric mucosa
in 40 participants (44%), appearing endoscopically as small
pale lesions. As ﬁrst described by Shaw et al17 in 2005, foci
of SRCC can also appear as small pale lesions. This may
mimic scars endoscopically; however, microscopically this
does not pose a diagnostic dilemma. In our analysis some
participants underwent up to 12 endoscopies with on
average 25 random plus additional targeted biopsy
samples per endoscopy. Except for 1, no scars were found
at baseline endoscopies, suggesting that scars were mostly
induced by prior gastric biopsy samples. Although
the shape of the lesion often suggests it is a scar rather
than an SRCC focus, these scars may hinder endoscopic
screening. Also, it is unknown if taking biopsy specimens
from the gastric mucosa and thereby inducing
inﬂammatory responses with release of cytokines
inﬂuences carcinogenic pathways in this population. On
the other hand, 4 SRCCs in this study were found because
of random biopsy sampling and not because of visible
lesions, indicating that random biopsy sampling cannot be
omitted in screening. Two of the 4 individuals with SRCC
foci were diagnosed at the ﬁrst screening endoscopy.
In summary, this study presents the largest cohort of
gastroscopy screening of a well-deﬁned group at risk of
HDGC. In these FDRs from HDGC patients without a
germline mutation in CDH1, endoscopic screening with
extensive biopsy collection resulted in the identiﬁcation
of DGC in 6% of asymptomatic persons. Screening may
therefore be justiﬁed in this population, although adjust-
ments in the endoscopic interval and stricter inclusion
criteria for the screening program could be considered.
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1 1 5 1 1 DGC (42)
2 1 1 1 DGC (56)
3 1 1 1 1 DGC (45)
4 1 4 1 1 DGC (23), IGC (57)
5 1 1 1 1 DGC (47)
6 1 1 1 DGC (67)
7 1 2 1 1 NA
8 1 1 1 1 NA
9 1 2 1 1 DGC (34)
10 1 3 3 2 NA
11 1 1 4 3 LBC (45)
12 1,2 4 2 1 DGC (71)
13 1 1 1 1 DGC (43)
14 1 1 1 DGC (50)
15 1 1 1 NA
16 1 1 1 GC (50)
17 1 3 1 DGC (64)
18 1 1 3 2 NA
19 1 1 3 2 DGC (36)
20 1 3 1 1 DGC (35)
21 2 3 1 DGC (76)
22 2 2 1 1 NA
23 2 1 2 1 DGC (46)
24 2 1 3 2 NA
25 2 1 2 1 DGC (52)
26 2 1 3 2 DGC (28)
27 2 1 2 1 DGC (65)
28 2 2 3 2 DGC (25)
29 2 1 1 DGC (54), CRC (55)
30 2 1 1 1 IGC (52)
31 2 6 3 2 MGC (32)
32 2 18 1 DGC (62)
33 2 4 3 2 DGC (37)
34 2 2 3 2 DGC (31)
35 2 1 1 1 DGC (31)
36 2 1 1 1 DGC (43)
37 2 3 1 and 4 1 and 3 LBC (55)
38 2 1 3 2 DGC (33)
39 2 1 3 2 DGC (33)
40 1 1 1 GC (48)
BC, Breast cancer; BO, bone cancer; BRAT, brain tumor; CRC, colorectal cancer; CUP, cancer of unknown primary; DBC, ductal breast cancer; DCIS, ductal carcinoma in situ;
DGC, diffuse-type gastric cancer; ES, esophageal cancer; ES SCC, esophageal squamous cell carcinoma; FDR, first-degree relative; GC, gastric cancer; HDGC, hereditary diffuse-type
gastric cancer; HL, Hodgkin lymphoma; HNC, head and neck cancer; IGC, intestinal-type gastric cancer; LBC, lobular breast cancer; LC, lung cancer; Leu, leukemia; MGC, mixed-
type gastric cancer; MM, malignant melanoma; NA, not available; NET, neuroendocrine tumor; NHL, non-Hodgkin lymphoma; NKI/AVL, Netherlands Cancer Institute/Antoni van
Leeuwenhoek; OC, ovarian cancer; PC, pancreatic cancer; PrCa, prostate cancer; RC, renal cancer; ThC, thyroid cancer; UGC, undifferentiated gastric cancer.
*2010 HDGC criteria: 1 Z 2 GC, 1 DGC < 50 y; 2Z 3 DGC; 3 Z 1 DGC < 40 y; 4 Z DGC and LBC, 1 < 50 y.
y2015 HDGC criteria: 1 Z 2 GC, 1 DGC; 2 Z 1 DGC < 40 y; 3 Z DGC and LBC, 1 < 50 y.
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SUPPLEMENTARY TABLE 1. Continued
GC or BC in FDR:
frequency (age)
GC or BC in second-degree relatives:
frequency (age)
Other cancer diagnoses in FDR and second-degree
relative: frequency (age)
GC: 1 (69); DBC: 1 (47) GC: 1 (69) DCIS: 1 (53)
GC: 1 (66) GC: 3 (53, 69, 73) CRC: 1 (66); BO: 2 (57, 80)
IGC: 1 (77) GC: 1 (70) RC: 1 (60)
BC: 1 (52) GC: 1 (50) LC: 1 (79); BO: 1 (23)
DGC: 1 (84); DBC: 1 (50)
DGC: 1 (70); GC: 1 (78) Thymoma: 1 (72)
DGC: 1 (34) GC: 1 (56) CRC: 1 (60)
DGC: 2 (31, 42)
GC: 2 (59, 65); DBC: 1 (53)
DGC: 1 (34); DBC: 1 (43) BC: 1 (40) Leu: 1 (80)
DGC: 1 (53) PC: 1 (70)
DGC: 2 (59, 65) RC: 1 (64); CRC: 2 (63, 65)
DGC: 1 (58); LBC: 1 (43) BC: 1 (49) PrCa: 1 (82)
DGC: 1 (50); GC: 1 (48) ThC: 1 (48)
DGC: 1 (54); GC: 1 (56) MGC: 1 (82) CRC: 1 (74)
DGC: 2 (67, 77); GC: 2 (53, 60); LBC: 1 (62) GC: 2 (NA); BC: 2 (NA) CRC: 1 (45); LC: 1 (59); HNC: 1 (55)
GC: 1 (52) GC: 3 (62, 64, 82) CRC: 4 (62, 74, 82, 83)
DGC: 1 (32) CRC: 1 (72)
BC: 1 (52) HL: 1 (18)
DGC: 1 (51); GC: 2 (22, 42) Thymoma: 1 (37)
IGC: 1 (73); UGC: 1 (51); GC: 2 (51, 69) GC: 5 (60, 68, 70, 70, 74) CUP: 1 (79); CRC: 1 (39)
DGC: 2 (42, 67) ES: 1 (70); CRC: 1 (49); CUP: 1 (NA); NHL: 1 (NA)
DGC: 3 (26, 45, 51) CRC: 1 (45)
DGC: 1 (34); IGC: 1 (53) ES SCC: 1 (53); CRC: 1 (80); LC: 1 (53)
DGC: 1 (58) DGC: 1 (85); GC: 1 (75) CUP: 1 (82); RC: 1 (63)
BRAT: 1 (NA)
DGC: 2 (59,71) CRC: 1 (NA)
CRC: 1 (74), OC: 1 (57)
DGC: 1 (65); LBC: 1 (62); GC: 1 (45) GC: 3 (48, 68, 79); BC: 1 (60) LC: 1 (48)
DGC: 2 (49, 74) IGC: 1 (72), GC: 1 (82)
DGC: 1 (63); GC: 2 (54, 71) GC: 4 (45, 51, 57, 72) BRAT: 1 (49)
DBC: 1 (50) BRAT: 1 (NA)
BC: 1 (44) NET lung: 1 (35); MM: 1 (NA)
DGC: 1 (79) PrCa: 1 (76); Leu: 1 (41)
GC: 1 (51)
DGC: 2 (49, 66) BC: 1 (52) PC: 1 (73); CRC: 1 (71); LC: 1 (NA)
DGC: 1 (51); IGC: 1 (78); BC: 1 (50)
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